Vineet Laboratories Limited
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
What Vineet files
- Others52
- Important44
- Board Meeting14
- Updates8
- Insider Trade2
- QIP/Rights/Pref.2
Vineet Laboratories' board has approved its financial results for the quarter and year ended March 31. The company turned profitable (0.13 Cr PBT) from a significant loss. Share issuance brought 29.08 Cr, boosting equity and cash to 16.70 Cr. Long-term borrowings decreased to 35.29 Cr.
Vineet Laboratories defers its scheduled board meeting to approve audited financial results for FY26 due to unavoidable circumstances. A new date will be announced shortly. This delays the release of full-year results.
Vineet Laboratories has a board meeting on July 15 to approve audited financial results for Q4 and the full financial year ending March 31, 2026. Investors await performance updates.
Vineet Labs has deferred financial results for the quarter and financial year as the Audit Committee did not approve them. The Company Secretary resigned. The trading window remains closed, impacting transparency. New dates for results approval will be announced.
Vineet Laboratories secured 'Trading' approval from BSE and NSE for 99,87,258 equity shares from its Rights Issue. These new shares are now listed and admitted to dealings on both exchanges, boosting liquidity and expanding the company's public float.